Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells

被引:0
|
作者
Motwani, M [1 ]
Li, XK [1 ]
Schwartz, GK [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Gastrointestinal Oncol Res Lab, New York, NY 10021 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Defects in cell cycle checkpoints can lead to chromosome abnormality, aneuploidy, and genomic instability, all of which can contribute to tumorigenesis. Recent studies and data presented in this study indicate that cells with compromised G(1) checkpoint endoreduplicate and become polyploid in response to microtubule inhibitors, Previous studies have shown that polyploid cells are unstable and lose chromosomes randomly to give aneuploidy, In this study, we show that endoreduplication and polyploidation can be prevented by inhibiting the cyclin-dependent kinases (Cdks) by flavopiridol, a synthetic flavone presently undergoing phase II clinical trials. In our initial studies, we treated MCF-7 cells with paclitaxel, which results in the arrest of cells in G(1) with 4n DNA content (pseudo G(1)), This was coincident with increased p53 and p21 protein expression and decreased cyclin E/Cdk2 kinase activity. In contrast, G(1) checkpoint-compromised MDA-MB-468 (p53-/- and pRb-/-) and p21-/- HCT116 do not arrest in the pseudo G(1) state after exposure to microtubule inhibitors and enter in the S phase with 4n DNA content. More than 60% of MDA-MB-468 cells accumulate with >4n DNA content after 72 h of nocodazole treatment. The MPM-2 labeling showed that 8n cells also undergo mitosis, These cells display deregulated and persistent activation of cyclin E/Cdk2 and cyclin B1/cdc2 kinase activity. Administration of flavopiridol after mitotic block results in the arrest of cells in the pseudo G(1) state and the dramatic decrease in cells containing >4n DNA content in MDA-MB-468 cells. The cyclin E/Cdk2 and cyclin B1/cdc2 kinase activities remained low after exit from mitosis, Furthermore, pRb was hypophosphorylated after the addition of flavopiridol in p21-deficient HCT116 cells, indicating the arrest of cells at the pseudo G(1) state, Based on these studies, we propose that flavopiridol preserves the genomic stability by preventing endoreduplication and polyploidy and thus has the potential to be used as a chemopreventive agent to prevent the occurrence of neoplasia.
引用
收藏
页码:924 / 932
页数:9
相关论文
共 50 条
  • [1] Flavopiridol, a cyclin-dependent kinase inhibitor
    Lansiaux, A
    Bailly, C
    BULLETIN DU CANCER, 2000, 87 (10) : 697 - 701
  • [2] Flavopiridol: a promising cyclin-dependent kinase inhibitor in cancer treatment
    Baghel, Uttam Singh
    Kriplani, Priyanka
    Patel, Neelam M.
    Kaur, Manpreet
    Sharma, Kapil
    Meghani, Monika
    Sharma, Abhay
    Singh, Deeksha
    Singh, Bhawani
    Setzer, William N.
    Sharifi-Rad, Javad
    Calina, Daniela
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024,
  • [3] Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials
    Senderowicz, AM
    INVESTIGATIONAL NEW DRUGS, 1999, 17 (03) : 313 - 320
  • [4] Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials
    Adrian M. Senderowicz
    Investigational New Drugs, 1999, 17 : 313 - 320
  • [5] Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy
    Tan, AR
    Swain, SM
    SEMINARS IN ONCOLOGY, 2002, 29 (03) : 77 - 85
  • [6] Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol
    Shapiro, GI
    CLINICAL CANCER RESEARCH, 2004, 10 (12) : 4270S - 4275S
  • [7] The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis
    Miyashita, Kazumi
    Shiraki, Katsuya
    Fuke, Hiroyuki
    Inoue, Tomoko
    Yamanaka, Yutaka
    Yamaguchi, Yumi
    Yamamoto, Norihiko
    Ito, Keiichi
    Sugimoto, Kazushi
    Nakano, Takeshi
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2006, 18 (02) : 249 - 256
  • [8] Cyclin-dependent kinase inhibitor, flavopiridol, sensitizes human hepatocelluler carcinoma cells to trail-induced apoptosis
    Miyashita, K
    Shiraki, K
    Fuke, H
    Inoue, T
    Yamanaka, Y
    Yamaguchi, YUMI
    Saitou, Y
    Sugimoto, K
    Nakano, T
    JOURNAL OF HEPATOLOGY, 2005, 42 : 108 - 109
  • [9] Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells
    Raju, U
    Nakata, E
    Mason, KA
    Ang, KK
    Milas, L
    CANCER RESEARCH, 2003, 63 (12) : 3263 - 3267
  • [10] Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development
    Zhai, SP
    Senderowicz, AM
    Sausville, EA
    Figg, WD
    ANNALS OF PHARMACOTHERAPY, 2002, 36 (05) : 905 - 911